Log In
BCIQ
Print this Print this
 

LY2623091

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionInhibits interaction between aldosterone and its receptor
Molecular Target Mineralocorticoid receptor
Mechanism of ActionMineralocorticoid receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard Indication Renal (unspecified)
Indication DetailsTreat chronic kidney disease (CKD) associated with diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today